Peter Langmuir, M.D. Executive Director, Medical Science AstraZeneca Explains the Side Effects of Vandetanib

Videos

Dr. Langmuir Explains the Side Effects of Vandetanib

Peter Langmuir, M.D. Executive Director, Medical Science AstraZeneca on the Advantages of Vandetanib in Medullary Thyroid Cancer 

Vandetanib Advantages in Medullary Thyroid Cancer

Peter Langmuir, MD, Executive Director, Medical Science AstraZeneca on Vandetanib in Medullary Thyroid Cancer 

Dr. Langmuir on Vandetanib in Medullary Thyroid Cancer

Peter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses a phase III double-blind study that investigated the use of vandetanib for 331 patients with unresectable locally advanced or metatastic medullary thyroid cancer.

eter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses the vandetanib clinical trials. 

Peter Langmuir, MD

Articles

Dr. Langmuir Explains the Side Effects of Vandetanib

Vandetanib Advantages in Medullary Thyroid Cancer

Dr. Langmuir on Vandetanib in Medullary Thyroid Cancer

Dr. Langmuir Discusses Vandetanib Clinical Trials